Incyte Corporation (NASDAQ: INCY) is set to announce its Q4 earnings results before market open this Tuesday. Analysts anticipate revenue growth of 14.8% year-on-year to $1.35 billion and adjusted earnings of $1.95 per share. The company has a strong track record of beating revenue estimates, and its stock has outperformed the broader biotechnology segment recently.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Incyte (INCY) Q4 Earnings: What To Expect
Incyte Corporation (NASDAQ: INCY) is set to announce its Q4 earnings results before market open this Tuesday. Analysts anticipate revenue growth of 14.8% year-on-year to $1.35 billion and adjusted earnings of $1.95 per share. The company has a strong track record of beating revenue estimates, and its stock has outperformed the broader biotechnology segment recently.